SpectraCure AB (ST:SPEC) — Market Cap & Net Worth
Market Cap & Net Worth: SpectraCure AB (SPEC)
SpectraCure AB (ST:SPEC) has a market capitalization of $894.96K (Skr8.32 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #30766 globally and #715 in its home market, demonstrating a -5.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SpectraCure AB's stock price Skr0.02 by its total outstanding shares 409667653 (409.67 Million). Also see SPEC total asset value for a full breakdown of the balance sheet.
SpectraCure AB Market Cap History: 2015 to 2026
SpectraCure AB's market capitalization history from 2015 to 2026. Data shows change from $62.66 Million to $894.96K (-32.51% CAGR). Also see SPEC operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
SpectraCure AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.23 Billion | 0.01% | #240 of 281 |
Weight: SpectraCure AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
SpectraCure AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SpectraCure AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for SpectraCure AB for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
7.91x
SpectraCure AB's market cap is 7.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $75.64 Million | $172.91K | -$6.37 Million | 437.42x | N/A |
| 2017 | $492.51 Million | $258.95K | -$8.70 Million | 1901.93x | N/A |
| 2018 | $335.96 Million | $596.00K | -$9.61 Million | 563.70x | N/A |
| 2019 | $1.16 Billion | $763.00 | -$13.69 Million | 1521525.58x | N/A |
| 2020 | $737.01 Million | $1.21K | -$15.41 Million | 608594.19x | N/A |
| 2021 | $258.57 Million | $5.75 Million | -$23.34 Million | 44.98x | N/A |
| 2022 | $221.32 Million | $539.00K | -$25.33 Million | 410.60x | N/A |
| 2023 | $170.17 Million | $318.00K | -$20.44 Million | 535.14x | N/A |
| 2024 | $112.20 Million | $19.53 Million | -$23.00 Million | 5.74x | N/A |
| 2025 | $6.87 Million | $868.00K | -$56.08 Million | 7.91x | N/A |
Competitor Companies of SPEC by Market Capitalization
Companies near SpectraCure AB in the global market cap rankings as of September 19, 2026. Review SPEC goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to SpectraCure AB by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
SpectraCure AB Historical Marketcap From 2015 to 2026
Between 2015 and today, SpectraCure AB's market cap moved from $62.66 Million to $ 894.96K, with a yearly change of -32.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr894.96K | -86.97% |
| 2025 | Skr6.87 Million | -93.88% |
| 2024 | Skr112.20 Million | -34.07% |
| 2023 | Skr170.17 Million | -23.11% |
| 2022 | Skr221.32 Million | -14.41% |
| 2021 | Skr258.57 Million | -64.92% |
| 2020 | Skr737.01 Million | -36.52% |
| 2019 | Skr1.16 Billion | +245.55% |
| 2018 | Skr335.96 Million | -31.79% |
| 2017 | Skr492.51 Million | +551.17% |
| 2016 | Skr75.64 Million | +20.70% |
| 2015 | Skr62.66 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of SpectraCure AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $894.96K USD |
| MoneyControl | $894.96K USD |
| MarketWatch | $894.96K USD |
| marketcap.company | $894.96K USD |
| Reuters | $894.96K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SpectraCure AB
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.